NEW YORK (GenomeWeb News) — Tripos today said a deal to sell its Discovery Research branch to Provid Pharmaceuticals may fall through after Provid said it is unable to pull together the cash it needs to make the acquisition.
As a result, Tripos said it has begun talking with “other parties” that it said have shown interest in buying the DR business, although the company said it could not assure that another suitor could find the money either.